Status:
NOT_YET_RECRUITING
High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)
Lead Sponsor:
University of Zurich
Conditions:
High Altitude Pulmonary Hypertension
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live \>2500m on 6-minute walk distance (6MWD)
Detailed Description
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will perform a 6-minute walk distance test near their living a...
Eligibility Criteria
Inclusion
- Permanently living \>2500 m
- HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
- Written informed consent
Exclusion
- Highlanders who cannot follow the study investigations,
- Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
- Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
- Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06489691
Start Date
July 1 2024
End Date
December 31 2024
Last Update
July 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aksay Medical Center
Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan